Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study

Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study

Yue Fei,1 Zhihong Xie,2 Yuanyuan Luo,3 Xiaolan Yong,4 Na Li,1 Rong Huang,1 Xiaolin Du,4 Yijing Zhu,4 Dongmei Lan,3 Yang Qi,3 Gang Cheng,1 Quanren Wang,1 Kai Shen1 1Department of Clinical Research, Jiangsu Hengrui Pharmaceuticals, Shanghai, People’s Republic of China; 2Phase I Clinical Trial Center,...

Full description

Saved in:
Bibliographic Details
Main Authors: Fei Y, Xie Z, Luo Y, Yong X, Li N, Huang R, Du X, Zhu Y, Lan D, Qi Y, Cheng G, Wang Q, Shen K
Format: Article
Language:English
Published: Dove Medical Press 2025-05-01
Series:Drug Design, Development and Therapy
Subjects:
mineralocorticoid receptor antagonist
pharmacokinetics
renal impairment
chronic kidney disease
Online Access:https://www.dovepress.com/pharmacokinetics-and-safety-of-hrs-1780-in-renal-impaired-subjects-a-m-peer-reviewed-fulltext-article-DDDT
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items